Indazol substituted 4-oxo-furo[3,2-c]pyridines

Disclosed are indazol substituted 4-oxo-furo[3,2-c]pyridine derivatives which are MCH1 receptor modulators and are as represented by the general formula (I), wherein: n is 1 or 2; R is NR1R2, wherein R1 and R2 are each independently selected from H and optionally substituted alkyl, or R1 and R2, together with the N atom to which they are attached, form a 4-7 membered optionally substituted heterocyclic ring which optionally contains 1 or 2 heteroatoms in addition to the N atom shown; R3 and R4 are each independently selected from H and alkyl, or R, R3 and R4 may combine to form an optionally substituted imidazolin-2-yl group; B is aryl or heteroaryl; and R5, R6 and R7 are each independently selected from hydrogen, hydroxy, alkoxy, alkyl, halo, trifluoromethyl or cyano. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier, excipient or diluent therefore for the treatment of obesity, anxiety, depression or non-alcoholic fatty liver disease.